Company news
Arcturus Therapeutics Holdings Inc. news in 2025
Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2025, newest first.
Arcturus Therapeutics to Attend Upcoming Investor Conference
November 23, 2025
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
November 9, 2025
Arcturus Therapeutics to Attend Upcoming Investor Conferences
November 3, 2025
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
October 27, 2025
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
October 21, 2025
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
August 10, 2025
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 23, 2025
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 29, 2025
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
June 22, 2025
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 11, 2025
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
April 21, 2025
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
April 9, 2025
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
March 5, 2025
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
March 4, 2025
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
February 23, 2025
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 13, 2025
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 13, 2025
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
February 3, 2025
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
January 30, 2025
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
January 9, 2025
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 5, 2025
Calls in 2025
- Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q3 2025 Earnings Call
Nov 10, 2025
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q2 2025 Earnings Call
Aug 11, 2025
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2025 Earnings Call
May 12, 2025
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q4 2024 Earnings Call
Mar 6, 2025
Transcript
Decks in 2025
- Technical Presentation (October 2025)
Technical · 10 slides · Oct 22, 2025
- ICIEM 2025
Conference · 11 slides · September 2025
- Technical Presentation (June 2025)
Technical · 42 slides · Jun 30, 2025